Instructions for Memantal (Memantine)
Release form
Coated tablets
Description Memantine
The tablets are covered with a film shell of white color, round, double-convex, with a wide risk on one side and the marking "M9MN" and "10" on the other.
1 tab.
memantina hydrochloride 10 mg
Auxiliary substances:
lactose monohydrate - 149.75 mg,
cellulose microcrystalline - 27.1 mg,
talc - 11.15 mg,
silicon dioxide colloidal - 1.25 mg,
magnesium stearate - 0.75 mg.
Shell Composition:
Opadray® white (lactose monohydrate - 2.16 mg,
hypromellose - 1.68 mg,
titanium dioxide - 1.56 mg,
macrogol 4000 - 0.6 mg) - 6 mg.
10 pcs - blister packs (3) - cardboard packs.
10 pcs - blister packs (6) - cardboard packs.
10 pcs - blister packs (9) - cardboard packs.
10 pcs - blister packs (10) - cardboard packs.
14 pcs. - blister packs (2) - cardboard packs.
14 pcs. - blister packs (8) - cardboard packs.
ATC codes
N06DX01 Memantine
Clinical-pharmacological groups / Group affiliation
Glutamate blocker of NMDA receptors. Preparation for the treatment of dementia
Active substance
memantina hydrochloride
Pharmacotherapy group
Dementia Treatment Tool
Storage Conditions
The drug Memantal should be stored in a place inaccessible to children at a temperature not higher than 25 ° C.
Best before date
The shelf life is three years.
Testimony:
moderate to severe alzheimer's dementia.
Method of use, course and dosage:
The treatment should be supervised by a doctor with experience in the diagnosis and treatment of dementia in Alzheimer's disease. Therapy should be initiated only if the person who regularly takes care of the patient is supervising the patient's administration of the drug Memantine. The diagnosis must be made in accordance with current recommendations.
The drug's tolerability and dose should be assessed regularly, preferably within three months of starting therapy. The clinical effectiveness of the drug Memantal and the tolerability of the therapy should then be regularly assessed in accordance with current clinical guidelines. The maintenance therapy can be continued indefinitely with a therapeutic effect and good tolerability. The use of the drug should be discontinued if the therapeutic effect is no longer observed or if the patient is not receiving treatment.
The drug Memantine is taken inside, 1 times/day, always at the same time, regardless of the meal. The dosing mode is set individually. It is recommended to start the treatment with a minimum effective dose.
The preparation is administered during the 1st week of therapy (days 1-7) at a dose of 5 mg/day, during the 2nd week (days 8-14) at a dose of 10 mg/day, during the 3rd week (days 15-21) at a dose of 15 mg/day, and during the 4th week at a dose of 20 mg/day. Maximum daily dose 20 mg.
In patients older than one year, and in patients with QC of 50-80 ml/min, no dose correction is required. For patients with moderate kidney failure (QC 30-49 ml/min), the daily dose is 10 mg. If the drug Memantine is well tolerated for 7 weeks, the dose can be increased to 20 mg as standard.
Instructions for dividing the pill
Place the tablet round side on a hard surface risking upwards. Press the forefinger and thumb of one of the hands against the opposite side
Terms of implementation
The drug Memantal is dispensed by prescription.
Nosology (ICD codes)
F00
Dementia in Alzheimer's disease
Pharmacological effect Memantal:
A remedy for the treatment of dementia. It is a non-competitive antagonist of glutamate NMDA-peceptors (incl. in the black substance), as a result of which it reduces the excessive stimulating effect of cortical glutamate neurons on neostriatum, which develops against the background of insufficient dopamine secretion. Reducing the flow of C2+ into neurons, reduces the possibility of their destruction.
It has nootropic, cerebrovazodilating, antihypoxic and psychostimulating effect. Improves weakened memory, increases the ability to concentrate, reduces fatigue and symptoms of depression, reduces the spasticity of skeletal muscle caused by diseases or brain damage.
